Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Genome-wide analyses reveal a highly conserved Dengue virus envelope peptide which is critical for virus viability and antigenic in humans.

Fleith RC, Lobo FP, Dos Santos PF, Rocha MM, Bordignon J, Strottmann DM, Patricio DO, Pavanelli WR, Lo Sarzi M, Santos CN, Ferguson BJ, Mansur DS.

Sci Rep. 2016 Nov 2;6:36339. doi: 10.1038/srep36339.

2.

Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

VanBlargan LA, Goo L, Pierson TC.

Microbiol Mol Biol Rev. 2016 Oct 26;80(4):989-1010. Review.

PMID:
27784796
3.

Structural Basis of Zika Virus-Specific Antibody Protection.

Zhao H, Fernandez E, Dowd KA, Speer SD, Platt DJ, Gorman MJ, Govero J, Nelson CA, Pierson TC, Diamond MS, Fremont DH.

Cell. 2016 Aug 11;166(4):1016-27. doi: 10.1016/j.cell.2016.07.020.

PMID:
27475895
4.

Computational analysis reveal inhibitory action of nimbin against dengue viral envelope protein.

Lavanya P, Ramaiah S, Anbarasu A.

Virusdisease. 2015 Dec;26(4):243-54. doi: 10.1007/s13337-015-0280-x.

5.

Antibody Binding Modulates Conformational Exchange in Domain III of Dengue Virus E Protein.

Moraes AH, Simonelli L, Pedotti M, Almeida FC, Varani L, Valente AP.

J Virol. 2015 Dec 4;90(4):1802-11. doi: 10.1128/JVI.02314-15.

6.

Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection.

Pinto AK, Brien JD, Lam CY, Johnson S, Chiang C, Hiscott J, Sarathy VV, Barrett AD, Shresta S, Diamond MS.

MBio. 2015 Sep 15;6(5):e01316-15. doi: 10.1128/mBio.01316-15.

7.
8.

Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope.

Robinson LN, Tharakaraman K, Rowley KJ, Costa VV, Chan KR, Wong YH, Ong LC, Tan HC, Koch T, Cain D, Kirloskar R, Viswanathan K, Liew CW, Tissire H, Ramakrishnan B, Myette JR, Babcock GJ, Sasisekharan V, Alonso S, Chen J, Lescar J, Shriver Z, Ooi EE, Sasisekharan R.

Cell. 2015 Jul 30;162(3):493-504. doi: 10.1016/j.cell.2015.06.057.

9.

Immunization with Immune Complexes Modulates the Fine Specificity of Antibody Responses to a Flavivirus Antigen.

Tsouchnikas G, Zlatkovic J, Jarmer J, Strauß J, Vratskikh O, Kundi M, Stiasny K, Heinz FX.

J Virol. 2015 Aug;89(15):7970-8. doi: 10.1128/JVI.00938-15.

10.

Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells.

Mengistu M, Ray K, Lewis GK, DeVico AL.

PLoS Pathog. 2015 Mar 25;11(3):e1004772. doi: 10.1371/journal.ppat.1004772. Erratum in: PLoS Pathog. 2015 Jun;11(6):e1004990.

11.

A game of numbers: the stoichiometry of antibody-mediated neutralization of flavivirus infection.

Pierson TC, Diamond MS.

Prog Mol Biol Transl Sci. 2015;129:141-66. doi: 10.1016/bs.pmbts.2014.10.005. Review.

12.

Functional analysis of dengue virus (DENV) type 2 envelope protein domain 3 type-specific and DENV complex-reactive critical epitope residues.

Pitcher TJ, Sarathy VV, Matsui K, Gromowski GD, Huang CY, Barrett AD.

J Gen Virol. 2015 Feb;96(Pt 2):288-93. doi: 10.1099/vir.0.070813-0.

13.

Variation of the specificity of the human antibody responses after tick-borne encephalitis virus infection and vaccination.

Jarmer J, Zlatkovic J, Tsouchnikas G, Vratskikh O, Strauß J, Aberle JH, Chmelik V, Kundi M, Stiasny K, Heinz FX.

J Virol. 2014 Dec;88(23):13845-57. doi: 10.1128/JVI.02086-14.

14.

Thermodynamic mechanism for the evasion of antibody neutralization in flaviviruses.

Maillard RA, Liu T, Beasley DW, Barrett AD, Hilser VJ, Lee JC.

J Am Chem Soc. 2014 Jul 23;136(29):10315-24. doi: 10.1021/ja503318x.

15.

Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement.

Edeling MA, Austin SK, Shrestha B, Dowd KA, Mukherjee S, Nelson CA, Johnson S, Mabila MN, Christian EA, Rucker J, Pierson TC, Diamond MS, Fremont DH.

PLoS Pathog. 2014 Apr 17;10(4):e1004072. doi: 10.1371/journal.ppat.1004072.

16.

The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.

VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC.

PLoS Pathog. 2013;9(12):e1003761. doi: 10.1371/journal.ppat.1003761.

17.

Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics.

Sharon J, Rynkiewicz MJ, Lu Z, Yang CY.

Immunology. 2014 May;142(1):1-23. doi: 10.1111/imm.12213. Review.

18.

Protein engineering strategies for the development of viral vaccines and immunotherapeutics.

Koellhoffer JF, Higgins CD, Lai JR.

FEBS Lett. 2014 Jan 21;588(2):298-307. doi: 10.1016/j.febslet.2013.10.014. Review.

19.

Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections.

Sautto G, Mancini N, Gorini G, Clementi M, Burioni R.

Biomed Res Int. 2013;2013:838491. doi: 10.1155/2013/838491. Review.

20.

Dissection of antibody specificities induced by yellow fever vaccination.

Vratskikh O, Stiasny K, Zlatkovic J, Tsouchnikas G, Jarmer J, Karrer U, Roggendorf M, Roggendorf H, Allwinn R, Heinz FX.

PLoS Pathog. 2013;9(6):e1003458. doi: 10.1371/journal.ppat.1003458.

Items per page

Supplemental Content

Support Center